# A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

> **NCT01847274** · PHASE3 · COMPLETED · sponsor: **Tesaro, Inc.** · enrollment: 596 (actual)

## Conditions studied

- Ovarian Neoplasms
- Platinum Sensitive Ovarian Cancer

## Interventions

- **DRUG:** Active comparator: Niraparib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01847274
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-21
- **Primary completion:** 2016-04-22
- **Final completion:** 2021-12-26
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01847274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01847274, "A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01847274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*